Latest Articles

Publication Date
Efficacy and Safety of Robotic Surgery With Sentinel Lymph Node Navigation in Obese Patients With Endometrial Cancer: A Retrospective Study - Cureus

Efficacy and Safety of Robotic Surgery With Sentinel Lymph Node Navigation in Obese Patients With Endometrial Cancer: A Retrospective Study Cureus

Published: April 16, 2025, 6:31 a.m.
Dr Lan on the Efficacy of Cadonilimab Plus Lenvatinib in Advanced Endometrial Cancer - OncLive

Dr Lan on the Efficacy of Cadonilimab Plus Lenvatinib in Advanced Endometrial Cancer OncLive

Published: March 28, 2025, 10:08 p.m.
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer - OncLive

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer OncLive

Published: March 17, 2025, 9:22 p.m.
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer - OncLive

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer OncLive

Published: March 16, 2025, 7:29 p.m.
Infigratinib shows promising efficacy and tolerability in pediatric achondroplasia - 2 Minute Medicine

Infigratinib shows promising efficacy and tolerability in pediatric achondroplasia 2 Minute Medicine

Published: March 11, 2025, 8:13 p.m.
The study on the clinical efficacy of endometrial receptivity analysis and influence factors of displaced window of implantation - Nature.com

The study on the clinical efficacy of endometrial receptivity analysis and influence factors of displaced window of implantation Nature.com

Published: March 1, 2025, 2:30 p.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central

Published: Feb. 28, 2025, 10:47 a.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - bmcwomenshealth.biomedcentral.com

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com

Published: Feb. 28, 2025, 10:47 a.m.
(PDF) The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors - ResearchGate

(PDF) The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors ResearchGate

Published: Feb. 14, 2025, 3:13 a.m.
(PDF) Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment - ResearchGate

(PDF) Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment ResearchGate

Published: Jan. 25, 2025, 1:07 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!